Hazlett, Burt & Watson’s iShares iBonds Dec 2032 Term Corporate ETF IBDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4K Buy
157
+2
+1% +$51 ﹤0.01% 795
2025
Q4
$4K Buy
155
+2
+1% +$51 ﹤0.01% 802
2025
Q3
$4K Buy
+153
New +$3.88K ﹤0.01% 752

Other funds holding IBDX

Hazlett, Burt & Watson's IBDX Position: Q1 2026 in Review

Hazlett, Burt & Watson increased its iShares iBonds Dec 2032 Term Corporate ETF (IBDX) stake by 1.3% in Q1 2026, buying an estimated $51 and bringing the position to 157 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #795.

Hazlett, Burt & Watson first reported a position in IBDX in Q3 2025 and has held it in 3 quarters since. 221 funds tracked by Wall St. Rank hold IBDX as of Q1 2026.

  • Hazlett, Burt & Watson held 157 shares of iShares iBonds Dec 2032 Term Corporate ETF worth $4K as of Q1 2026.
  • Hazlett, Burt & Watson bought 2 iShares iBonds Dec 2032 Term Corporate ETF shares in Q1 2026, an estimated $51.
  • iShares iBonds Dec 2032 Term Corporate ETF made up ﹤0.01% of Hazlett, Burt & Watson's portfolio in Q1 2026, its #795 holding.
  • Hazlett, Burt & Watson first reported a position in iShares iBonds Dec 2032 Term Corporate ETF in Q3 2025 and has held it in 3 quarters since.
  • 221 funds tracked by Wall St. Rank held iShares iBonds Dec 2032 Term Corporate ETF as of Q1 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q1 2026, filed 14 May 2026.